INSIGHT-ESPRIT
Patients suffering from sustained acute or chronic illness often have decreased white blood cell and platelet counts as well as anemia, and bone marrow studies routinely show only decreased numbers of blood precursor cells. While much has been recently learned about the cause of isolated anemia, the pathogenesis of true bone marrow failure (i.e., low bone marrow cellularity and low counts in multiple blood lineages) has remained elusive. In this issue of the JCI, Chen et al. present evidence that overactivation of mammalian target of rapamycin signaling in HSCs is found in two mouse models of bone marrow failure, and they show that treatment with rapamycin significantly normalizes the low blood counts.
The recent explosions in genomics and systems biology highlight the usefulness of mathematic techniques, such as differential equations and linear algebra, for the manipulation and analysis of large data sets. One powerful mathematical concept for simplifying and understanding such complex systems is the eigenvalue, a dominant vector within a complex linear system, around which other vectors rotate and relate. The effects of an eigenvalue explain and dominate those of others in the system.
The concept of the eigenvalue has important implications beyond mathematical models. It is especially important in experimental biology and clinical medicine, as investigators search for single molecules or pathways whose effects dominate complex reactions within a cell. Even if we do not always have at hand detailed mathematical models and thus cannot always strictly identify eigenvalues a priori, specific pharmacologic interventions can sometimes reveal them experimentally, thereby simplifying an otherwise bewildering network of interacting pathways.
In this issue of the JCI, Chen et al.
(1), provide us with an intriguing example of a biological eigenvalue unveiled by pharmacologic manipulation. They present compelling evidence linking acute and chronic activation of the innate immune system to suppression of HSC differentiation. They go on to identify the mammalian target of rapamycin (mTOR) pathway as a dominant signal transduction pathway mediating this effect. These results link chronic inflammation with stem cell aging and, furthermore, make the powerful suggestion that treatment with the mTOR inhibitor rapamycin might mitigate these effects.
Hematopoiesis is regulated by the immune system: growth factors and cytokines
Ever since MHC class II antigens were found to be expressed on early myeloid progenitor cells as well as traditional antigen-presenting cells (2), the hematopoietic system has been appreciated as a potential regulator and target of adaptive immune activity. Indeed, T cells activated via engagement of their TCRs and costimulatory molecules by activating cells (perhaps including hematopoietic progenitors themselves) promote myeloid differentiation through the secretion of GM-CSF and IL-3, resulting in increased neutrophil and red blood cell production from HSCs, both under basal conditions and after stem cell transplantation (3, 4) .
(1) show that extremely high levels of activation of the innate immune system, either through the global inactivation of the gene encoding forkhead box P3 (FoxP3) in scurfy mice or by injection of LPS, severely abrogate HSC differentiation, resulting in profound loss of B lymphoid, neutrophilic, and erythropoietic lineages. These effects could be largely prevented through inhibition of TNF-a, IL-6, and CCL2 (but not IFN-g). Chen and colleagues went on to show that both TNF-a and IL-6 induce phosphorylation of the mTOR target ribosomal protein S6 kinase (S6K) in HSCs (1). Perhaps most remarkably, inhibition of the mTOR pathway with rapamycin largely ameliorated these suppressive effects in both mouse models. Clearly, innate immune activation involves the action of multiple soluble cytokines and insoluble ligand-receptor interactions, which in turn trigger multiple cellular pathways, of which mTOR is only one. However, mTOR in HSCs must act as a "biological eigenvalue," coordinating most of the inhibitory effects in HSCs of this complex set of intracellular responses to external signals of innate immune activation. Thus, while TNF-a, IL-6, and CCL2 activate multiple signal transduction pathways within target cells, not the mTOR pathway alone, the striking effects of rapamycin demonstrate that among these pathways, mTOR plays an integrating, dominant role, at least within early hematopoietic cells.
High levels of TNF-α cause overt HSC damage
How mTOR activation prevents HSCs from proliferating and differentiating to produce mature blood cells is less clear but appears likely to be the result of direct stem cell toxicity via unclear mechanisms. Chen et al. found that the number of bone marrow cells expressing the cell surface proteins that typically appear on HSCs actually rose slightly, even while hematopoiesis declined, but many of these HSCs were dead or dying (1). Thus, the apparent increase in cells bearing HSC markers is likely to be an artifact of the stress induced by the acute toxicity of high levels of activation of the innate immune system, which includes high levels of circulating cytokines.
Direct damage of HSCs might underlie recent findings from other laboratories that, like TNF-a, chronic IFN stimulation causes an apparent increase in cells detected as expressing markers of HSCs but a decrease in HSC function. This artifact is most clear in the case of IFN-induced increases in the number of Sca-1 + ckit -lincells (the traditional cell surface signature of HSCs) that were determined to occur not because HSCs proliferate but, instead, because cell surface expression of Sca-1 was directly induced on Sca-1 -non-HSCs (5, 6). Cell surface Sca-1 has also been demonstrated to be induced on previously Sca-1 -hematopoietic cells by TNF-a (7), and this might at least partially explain the findings of Chen et al. (1) . Whether alterations in cell surface proteins other than Sca-1 can explain the apparent lack of increase in hematopoiesis despite increased numbers of cells apparently marking as HSCs in the paper by Chen et al. (1) is not clear, but it is clearly possible. In any case, the results of Chen and colleagues make it clear that direct cell damage can readily be detected on early hematopoietic cells (1), which include both HSCs and slightly more differentiated non-HSCs. Most importantly, no study has yet shown an increase in the number of functional, transplantable HSCs after exposure to cytokine mediators of inflammation, including IFN, TNF-a, and IL-6, i.e., numbers of cells with a particular cell surface phenotype do not equal numbers of functional stem cells. Limiting dilution transplantation experiments to quantitatively probe this possibility would be very interesting. But whether cells marking as HSCs increase in number or not after extremely high levels of activation of the innate immune system, the important point is that from a functional point of view, they are not able to fend off the powerful effects of the innate immune system on HSC integrity and differentiation capacity, irrespective of stem cell cycling per se.
mTOR, rapamycin, and the complications of innate immune activation
Whether or not it is true that HSC numbers rise, the significance of functional hematopoietic suppression by mediators of inflammation is real enough. The findings of Chen et al.
(1) will clearly intrigue every clinician who has cared for severely ill patients, often in intensive care units, whose pancytopenia defies both explanation and treatment. Perhaps, as suggested by Chen et al. (8) , mTOR inhibition acts to prevent premature stem cell aging and exhaustion induced under the veil of innate immune activation. The possibility that short-term rapamycin treatment could ameliorate this and perhaps other manifestations of pathologic cytokine activation should inspire careful clinical trials in the future. Such trials will exemplify the clinical investigator's understanding and application of eigenvalues, both mathematical and biological, to the untangling of the complex web of the cell for the understanding and treatment of disease.
